Illumina (ILMN) Launches VeriSeq NIPT Solution In Europe
Zacks Investment Research | Apr 13, 2017 08:58AM ET
Global leader in the field of DNA sequencing and array-based technologies, Illumina, Inc. (NASDAQ:ILMN) recently announced the launch of a solution pertaining to its noninvasive prenatal testing (NIPT) range in Europe. The product, VeriSeq NIPT solution, is a CE-IVD marked next-generation sequencing (NGS)-based approach to NIPT. The solution helps laboratories provide accurate information on fetal chromosome abnormality in around a day.
This solution helps in providing accurate information on the fetal chromosome status as early as 10 weeks gestation, using a single maternal blood draw. The solution is also claimed to detect chromosomal disorders like Down syndrome, Edwards syndrome, Patau syndrome and some other sex chromosome-related disorders.
Owing to its high sensitivity and specificity, this NGS-based NIPT minimizes the need for complicated invasive testing procedures. The advanced technology will lead to faster and highly sensitive results and minimum test failures.
Further, Illumina claims this procedure to be time friendly in comparison to other alternative methods. With the VeriSeq NIPT, laboratories can process up to 96 samples in approximately one day. Also, it offers rapid workflow and unprecedented automation.
Notably, while launching the solution, the company formed a partnership with CooperGenomics in Europe. CooperGenomics is supposed to use the VeriSeq NIPT protocol to advance its NIPT test offering.
With the growing popularity of NGS-based technology all over the world, we believe the launch of VeriSeq NIPT should strengthen Illumina’s foothold in Europe.
According to Markets and Markets, the NIPT market is anticipated to reach a worth of $2.88 billion by 2021 from $1.35 billion in 2016, at an impressive CAGR of 16.4%. Thus, the company is making efforts to cash in on this booming market.
Recent Developments
Illumina has been in the headlines of late, courtesy of its innovative and strong pipeline. Among the company’s recent product launches, NovaSeq, a brand new architecture designed to be the most powerful sequencer, is worth a mention. The company is also introducing meaningful improvements in both performance and cost per base and is likely to expand the customer base as well.
The company has also launched products like the RUO version of TruSight Tumor 170 or TST 170 which are accelerating the adoption of genomics. TST 170's enrichment-based target panel simultaneously analyzes DNA and RNA and assesses the mutation status of genes commonly associated with solid tumors to provide a deep view of the underlying genetics of cancer.
Zacks Rank & Key Picks
Currently, Illumina carries a Zacks Ranks #3 (Hold). Better-ranked stocks in the broader Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.